PRESS RELEASE: Canadian Court Finds Infringement of Lipitor Crystal Form Patent

Canadian Court Finds Infringement of Lipitor Crystal Form Patent

NEW YORK -- Pfizer Inc said today that the Canadian Federal Court in Toronto has ruled that Pfizer’s patent covering a crystalline form of atorvastatin, the active ingredient in Lipitor, would be infringed by Ranbaxy Laboratories Limited’s process for making their proposed generic atorvastatin product.

The court granted the company’s application for an order preventing Ranbaxy from launching its product until expiration of the patent (Canadian Patent No. 2,220,018) in July 2016. Ranbaxy may seek to appeal this decision.

The court denied the company’s application for a prohibition order in connection with a second patent covering a process for making amorphous atorvastatin (Canadian Patent No. 2,220,455), which also expires in July 2016.

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.